2.2.0.7 false ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE 1040 - Disclosure - ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDPerShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE 0 ceph_AcquiredInProcessResearchAndDevelopmentExpenseDisclosureAbstract ceph false na duration No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 3 ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE 1 us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false terselabel false 1 false false false false 0 0 <table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 4.  ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE   In 2009, we recognized acquired in-process research and development expense of:   ·                  $9.4 million in exchange for the elimination of the $15.0 million milestone and royalty payments associated with the celecoxib license agreement and Acusphere patent rights relating to its HDDS technology;   ·                  $30.0 million in exchange for the exclusive, worldwide license rights to LUPUZORTM, acquired from ImmuPharma;   ·                  $0.8 million in exchange for exclusive sublicense rights to bendamustine hydrochloride in China and Hong Kong, acquired from SymBio; and   ·                  $6.0 million in exchange for license rights to certain of XOMA Ltd.s proprietary antibody library materials.  </td></tr></table> 4.  ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE   In 2009, we recognized acquired in-process research and development expense false false false us-types:textBlockItemType textblock Description, amount and terms involving research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 68 -Paragraph 14 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-FGC -Chapter 3 -Paragraph 56, 57 -IssueDate 2006-05-01 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 false 1 2 false UnKnown UnKnown UnKnown false true